ZENOTECH LABORATORIES LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 37 | 38 | 37 | 39 | 40 |
| EBITDA (ex other income) | 17 | 17 | 13 | 12 | 5 |
| margin % | 47.8 | 43.4 | 35.8 | 30.9 | 12.5 |
| Owners' profit | 22 | 12 | 8 | 6 | (1) |
| EPS, as reported (₹) | 3.63 | 1.90 | 1.36 | 0.92 | 0.18 |
| ROE % · ROCE % | 31.4 · 14.2 | 14.1 · 17.3 | 9.2 · 12.0 | 5.8 · 10.9 | (1.1) · 4.2 |
| Debt / equity (x) | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 18 | 21 | 12 | 9 | 10 |
| Capex | (2) | (6) | (4) | (4) | (8) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 9 | 10 | 11 | 9 | 10 | 12 | 9 |
| Profit before tax | 2 | 2 | 3 | 3 | 1 | 1 | 3 | (1) |
| Net profit | 1 | 1 | 2 | 1 | 1 | (1) | 2 | (3) |
| EPS (₹) | 0.21 | 0.22 | 0.28 | 0.20 | 0.16 | 0.14 | 0.32 | 0.52 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 29 Aug 2026 · Notice of 37th AGM and remote e-voting by Zenotech Laboratories | compliance | minimal | — | — |
| 28 Aug 2026 · Notice of 37th AGM and Annual Report for FY 2025-26 | board shareholder meetings | medium | — | — |
| 28 Aug 2026 · Annual Report 2025-26 and Notice of 37th AGM with Sun Pharma RPT | board shareholder meetings | medium | — | — |
| 24 Aug 2026 · Newspaper advertisement for 37th AGM via video conferencing on September 25, 2026 | compliance | minimal | — | — |
| 22 Aug 2026 · Zenotech Laboratories 37th AGM scheduled for September 25, 2026 via VC | board shareholder meetings | low | — | — |
| 29 Jul 2026 · Zenotech Labs Q1 FY27 results published in newspapers | compliance | minimal | — | — |
| 28 Jul 2026 · Board approves Q1 FY27 results, 37th AGM on Sep 25 | board shareholder meetings | low | — | — |
| 28 Jul 2026 · Q1 FY27 results: Zenotech swings to Rs 46 lakh loss vs profit YoY | results | high | — | — |
| 14 Jul 2026 · Compliance certificate filed with BSE for Q1 FY27 under SEBI depository rules | compliance | minimal | — | — |
| 13 Jul 2026 · Board meeting on July 28, 2026 to consider Q1 FY27 standalone results | results | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 39.0 | 28.9 | 110 of 169 | 35% |
| P/B | 2.9 | 3.3 | 73 of 163 | 55% |
| ROCE | 4.2 | 10.8 | 131 of 183 | 29% |
| ROE | (1.1) | 10.4 | 150 of 171 | 12% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 9.3 | 17.5 | 125 of 165 | 24% |
| Revenue growth | (20.2) | 16.3 | 140 of 161 | 13% |
| Profit growth | (356.2) | 30.9 | 155 of 158 | 2% |
| Market cap | 272 | 839 | 109 of 182 | 40% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
